Key facts
- It has raised $95.0M across 3 recorded rounds; the latest was PIPE in Feb 2022.
- 4 institutional filers report fund marks on Edgewise Therapeutics across 16 filings.
- Edgewise Therapeutics has filed 2 Form Ds with the SEC since 2019, most recently Dec 2020 ($95.0M sold to 21 investors).
Free account
See the evidence behind this price
- ·Post-money valuations for all 3 rounds
- ·Watchlist + deal alerts for Edgewise Therapeutics
Create free account
No card required
Funding rounds
3 roundsAbout Edgewise Therapeutics
- Industry
- Drug Discovery
PA Mark — not yet priced
Edgewise Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Edgewise Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
4 filers · latest Jun 20264 SEC-registered funds reported 16 fair-value marks on Edgewise Therapeutics between Apr 2025 and Jun 2026. Filer-level marks and implied $/share are available to Pro members.